Traders assign a strong 92.5% probability against a new COVID variant of concern emerging before 2027 because ongoing genomic surveillance shows SARS-CoV-2 continuing to evolve primarily within established Omicron sublineages such as NB.1.8.1 and XFG, without any lineages meeting the criteria for elevated transmissibility, severity, or immune escape that would trigger a VOC designation. Recent WHO and ECDC assessments through mid-2026 list no active variants of concern, with monitored strains like BA.3.2 exhibiting decreasing prevalence and no measurable rise in hospitalizations or deaths. Updated 2026-2027 vaccines target circulating JN.1 descendants, while broad population immunity from prior infections and vaccinations further dampens the impact of incremental mutations. A sudden antigenic shift could still alter this consensus, but current trends and monitoring systems support the market's view of limited near-term risk.